Knowing that HER2 could also represent an important therapeutic target in KRAS wild-type metastatic colorectal cancer patients resistant to anti-EGFR treatment, the authors determined the prevalence rate for HER2 amplification in KRAS wild-type samples, which were almost identical (5.1% and 5.2%) [10,14,49,52,53]. This evidence concerns the gene KRAS and metastatic colorectal cancer.